anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an extraction process of a lotion and an extract thereof in the technical field of lotion preparation, wherein the extraction process comprises the following steps: step one, pretreatment: weighing the medicinal materials for standby; step two, extracting and concentrating: placing the medicinal materials in a multifunctional extraction tank, soaking in water, decocting for two times, filtering the decoction with filter cloth, and mixing the filtrates to a liquid storage tank for use; pumping the filtrate into a single-effect concentration unit for concentration, and standing overnight. Step three, filtering: taking supernatant after the concentrated solution is stood, and placing the supernatant into a tube type centrifuge for centrifugation. Step four, preparing liquid: according to the batch extraction and preparation requirements, weighing sodium benzoate, dissolving with a proper amount of purified water, placing the liquid medicine after standing and centrifugation in a clean stainless steel barrel, heating and boiling for 30 minutes, stopping heating, adding sodium benzoate, stirring to uniformly mix, and preparing the liquid medicine. And fifthly, filling and labeling. And step six, packaging. The invention prepares the Hongbihao prescription from decoction into lotion, which is convenient for patients to use.
FIELD: pharmacology, veterinary. SUBSTANCE: desired compounds have common formula   where m=1 or 2, n=0, 1 or 2, A is lower alkyl, naphthyl or optionally substituted phenyl, B is lower alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, phenyl or heteryl; R 1  is halogen, lower alkoxyl, R 2  is lower akyl, lower alkanoyloxymethyl or -CH 2 -S-Het group where Het is heteryl. Said compounds having formula   are prepared by interaction of compound having formula   with halogenating agent. Thus obtained product having formula   is affected by interaction with compound having formula MS(O) b B where M is hydrogen or cation of metal. Compound having formula   is prepared by interaction of compound having formula   with compound having formula ZS(O) n B where Z is leaving group. Said interaction is carried out in the presence of organic or inorganic base in aprotic polar or nonpolar solvent at (-60)-(+40) C. EFFECT: improved quality of desired product, improved efficiency of the method. 6 cl, 4 tbl
This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
FIELD: medicine, vascular surgery. SUBSTANCE: method involves administration of the curative mixture consisting of heparin, hydrocortisone, chymotrypsin, ampicillin and novocaine solution (two or three injections) into paravasal tissue of thrombus-containing segment. Intrathrombotic infusion of rheopolyglucin-celiase-heparin mixture is performed by continuous intravenous catheterization of posteriotibia vein. Invention can be used for treatment of leofemoral venous thrombosis and provides the uniform distribution of thermobolytic agent in the zone of thrombotic process. EFFECT: enhanced effectiveness of thrombolytic therapy, improved regional hemodynamics, decreased hospitalization period, decreased complications and lethality. 1 dwg
CRSwNP patients scheduled for medically-indicated sinus surgery will undergo screening ELIspot assay to identify patients with fungal sensitivity based on positive fungal induced interleukin 4 (IL-4) ELIspot. Enrolled fungal sensitive CRSwNP patients will undergo their sinus surgery and randomized into either placebo or itraconazole 200 mg taken by mouth twice a day (PO BID) for 24 weeks in addition to standardized post-surgical regimen (9 days of perioperative prednisone, saline irrigations and pain medication as needed). Patients will be followed as outpatient in rhinology clinic for 48 weeks total. During these post-op visits, compliance with medications will be determined. Patients will be questioned about any possible side effects or adverse events to post-operative medications. Then, the patients will be evaluated by 2 nasal specific quality of life questionnaires and nasal endoscopy. The goals of the nasal endoscopy are to evaluate the state of the sinus mucosa and to determine recurrence of nasal polyps.
A system for controlling a target controlled infusion for administering a drug to a patient (P) comprises at least one infusion device ( 31 - 33 ) for administering a drug to the patient (P) and a control device ( 2 ) configured to control operation of the at least one infusion device ( 31 - 33 ) in order to establish a drug concentration at an effect site within the patient (P) at or close to a target concentration. The control device ( 2 ) is configured to execute a target controlled infusion protocol using a mathematical model modelling a drug distribution in the patient's body for controlling operation of the at least one infusion device ( 31 - 33 ). The control device ( 2 ) is further configured to store, at a multiplicity of points in time (T i  . . . T i+3 ) during execution of said target controlled infusion protocol, information derived from said mathematical model in a memory ( 21 ), to maintain at least a portion of said information in said memory ( 21 ) after a stop of execution of the target controlled infusion protocol, and to use said information in case of a start of execution of a target controlled infusion protocol after a prior stop.
This study is a retrospective study. Enrollment study. Enrolled in the Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Department of Liver Histology, Department of Hepatology, Chronic HBV HBV infection. The data collected included patient gender, . The data collected included patient gender, . The data collected included the patient's gender, age, HBV age of infection, past family history, etc., the age of the collected subjects, the current family history, etc., the liver histopathological diagnosis information collected in the group, and the liver disease examination Clinical toxicities and indicators, including serological diagnostic information, clinical toxicities and indicators for liver disease tests, including serological diagnostic information, clinical toxicities and indicators for liver disease tests, including serum HBV DNA HBV DNAHBV DNAHBV DNA HBV DNA content, HBsAg/HBsAg/HBsAg/HBsAg/anti-HBsHBsHBs, HBeAg/HBeAg/HBeAg/HBeAg/HBeAg/anti-HBe content, biochemical indicators coagulation function and routine data. Content, biochemical indicators, coagulation function and routine data. Content, biochemical indicators, coagulation function and routine data. Observe patient demographic data, HBV DNA HBV DNAHBV DNAHBV DNA HBV DNA content, HBsAg/HBsAg/HBsAg/HBsAg/HBsAg/anti-HBsHBsHBs, HBeAg/HBeAg/HBeAg/HBeAg/HBeAg/HBeAg/anti-HBe HBe content, biochemical indicators, coagulation Correlation between function and routine, coagulation function and conventional indicators and liver histological changes. Explore the relevance of effective diagnosis of liver changes. To explore the characteristics of clinical indicators that can effectively diagnose liver histopathological changes, and to provide clinical indicators for patients with chronic hepatitis B to receive timely treatment of histopathological changes, and provide important evidence for patients with chronic hepatitis B to receive timely treatment.
PROBLEM TO BE SOLVED: To inhibit oxidation of a medically effective component and the generation of discoloring or the like, meaning the preservation of an application agent stably for a long time, especially even when it is highly susceptible to effect of oxygen by holding a medically effective composition on one surface of a sheet-shaped support body to be sealed into a pack container having a deoxygenation effect. SOLUTION: An application agent has a medically effective composition held on one surface of a sheet-shaped support body to be sealed into a pack container having a deoxygenation effect. A deoxygenation agent sealed in is placed into the pack container to be possibly kept in contact with a gas in the pack container. To be more specific, the deoxygenation agent is directly sealed into the pack container. In other words, the deoxygenation agent, for example, in a powdery, granular, solid form or the like may be merely put into the pack container. The agent may be securely applied into the pack container. The ordinary deoxygenation agent is also usable. The deoxygenation agent herein used preferably has immediate effect (less required period of deoxygenation) or it may be of a self-reacting type or water dependent type.
BACKGROUND: While observation studies have shown a positive correlation between inflammatory bowel disease (IBD) and the risk of nonmalignant digestive system diseases, a definitive causal relationship has not yet been clearly established.
METHODS: Mendelian randomization (MR) was employed to investigate the potential causal association between genetic susceptibility to IBD and nonmalignant gastrointestinal diseases. Genetic variants were extracted as instrumental variables (IVs) from a genome-wide association study (GWAS) meta-analysis, which included 12,194 cases of Crohn's disease (CD) and 28,072 control cases of European ancestry. The GWAS for ulcerative colitis (UC) included 12,366 UC and 33,609 control cases of European ancestry. All IVs reached genome-wide significance (GWAS p value <5 × 10-8). Summary-level data for acute pancreatitis (AP), irritable bowel syndrome (IBS), gastroesophageal reflux disease, cholelithiasis, and CeD (celiac disease) were obtained from the GWAS meta-analysis and the FinnGen dataset. Summary-level data on relevant inflammatory factors were provided by the International Genetic Consortium. Univariate MR analysis was conducted using inverse variance weighting as the primary method for estimating causal effects. Multivariate MR analyses were also performed to detect possible mediators.
RESULTS: Genetic susceptibility to UC was associated with an increased risk of AP (OR = 1.08; 95% CI = 1.03-1.13; p=0.002) and IBS odds ratio (OR] = 1.07; 95% confidence interval (CI] = 1.03-1.11; (p < 0.001). In terms of potential mediators, interleukin 6 (IL-6) had a driving effect on the association between UC and AP. There was no apparent evidence of increased risk with CD. Meanwhile, genetic susceptibility to CD increases the risk of CeD (OR = 1.14; 95% CI = 1.03-1.25; p=0.01).
CONCLUSIONS: The evidence suggests that UC is associated with an elevated risk of AP and IBS, and IL-6 may be responsible in AP. CD is associated with an increased risk of developing CeD. Implementing a proactive monitoring program for assessing the risk of gastrointestinal diseases in UC patients, particularly those with elevated IL-6 levels, may be of interest. In addition, the presence of AP and IBS may indicate the presence of UC. Preventing CeD is an essential consideration in the therapeutic management of patients with CD.
BACKGROUND: In the European Union, rare diseases are defined as diseases that affect maximum 5 in 10,000 citizens. These diseases are typically associated with a high unmet medical need. To stimulate development and authorisation of medicines for rare diseases ('orphan conditions'), the European Commission (EC) can grant orphan designations. In order to enable systematic evaluation and communication of the diseases for which designated orphan medicines have (not) been developed and authorised, we aimed to investigate the feasibility of important disease terminology systems for mapping orphan conditions and therapeutic indications.
METHODS: We selected all designated orphan medicines that were authorised by the EC during 2022-2023 from the EC's Union Register of medicinal products. For these medicines, we extracted orphan conditions and associated therapeutic indications at initial marketing authorisation. The orphan conditions and separate elements of therapeutic indications such as target disease or condition, severity criteria and target population were assessed for availability in six major disease terminology systems: ICD-10, ICD-11, MedDRA, MeSH, Orphanet nomenclature of rare diseases, and SNOMED CT. Descriptive statistics were used to describe the ability of each disease terminology system to map orphan conditions and elements of therapeutic indications.
RESULTS: During 2022-2023, 37 designated orphan medicines were authorised that were designated for 40 orphan conditions (of which 37 unique) and granted 39 therapeutic indications (of which 37 unique). Overall, SNOMED CT covered most descriptions of orphan conditions (33/37, 89 %) and target diseases or conditions within therapeutic indications (28/37, 76 %). However, when allowing descriptions to be partly included and/or complemented by additional words, SNOMED CT, the Orphanet nomenclature, ICD-11 and MedDRA all had high coverage (92-97 %). Other elements than target diseases or conditions within therapeutic indications were mostly lacking.
CONCLUSIONS: Regulatory data concerning orphan conditions and therapeutic indications of designated orphan medicines seem to be best covered by SNOMED CT. However, which disease terminology system best facilitates systematic evaluation and communication about development and authorisation of designated orphan medicines also depends on the specific use case. Given the frequent use of SNOMED CT in healthcare settings, it may also facilitate interoperability between regulatory and healthcare data, while for example ICD-11 may be better suited to generate statistics concerning drug development for rare diseases.
Rectal cancer patients, ycTNM stage II, III, and IV (AJCC 8th), clinically stratified in the pre-cachectic or cachectic stage according to Fearon K et al. definition. That will be subject to curative intent resection or palliative surgery through any approach (open, laparoscopic, or robotic).
Pazopanib has shown a promising anti-cancer activity as a single agent tyrosine kinase inhibitor. Activity against multiple tumors such as renal cell carcinoma (RCC) and neuroendocrine tumors have been documented, and it recently gained FDA approval for the treatment of metastatic kidney cancer. Also, an impressive activity as a single agent was recently reported in non-small cell lung cancer (NSCLC) in the neoadjuvant setting, where tumor shrinkage occurred in 86% of patients. Encouraging activity has also been seen in cervical cancer, ovarian cancer and soft tissue sarcomas. Multi-kinase targeting is an approach that may prove beneficial in a number of patient populations. In particular cancers such as breast, colon, pancreas etc., patients represent heterogeneous population of small groups based on genetic analyses. Some of these populations may benefit when multiple agents are given which have similar, but distinct targets of action. Dosages and therefore associated toxicities might be reduced by such an approach.
The present invention is directed to transdermal drug delivery composition designed for the effective administration of a pharmacological agent having a formulation utilizing specially formulated ethosomes or transferosomes, enabling penetration of both the stratum corneum and dermis layers of the skin. The ethosomes, characterized by their non-polar and fat-soluble nature, incorporate isopropyl alcohol or ethanol as the alcohol component. Introducing lipid-based vesicles with remarkable proficiency in encapsulating medications and immunosuppressants. This unique composition significantly enhances the penetration of the stratum corneum layer. This ensures precise delivery to affected areas upon topical application. By transcending the limitations of conventional treatments, the disclosed method holds substantial promise for advancing therapeutic outcomes and elevating the overall patient experience.
An ascorbic acid-based composition and related method for the treatment of aging or photo-damaged skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0 %(w/v) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the composition also includes non-toxic zinc salt, tyrosine compound, and/or cosmetically acceptable carrier. In addition, the composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. The topical composition may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.
The present invention relates to gene transfer composition using a tri-block polymer electrolyte being polyethyleneimine-polylactic-acid-polyethylene-glycol. The polyethyleneimine- polyethylene-glycol di-block copolymer can be coupled to polyethyleneimine, thereby preparing polyethyleneimine-polylactic-acid-polyethylene-glycol being a tri-block polymer electrolyte. The cationic polyethyleneimine generates a complex with negatively charged, small interfering ribonucleic acids (siRNAs) while a hydrophobic polylactic acid forms a hard core. The polyethylene glycol can be combined with polyethyleneimine to reduce the toxicity of the polyethyleneimine, thereby enhancing the solubility, stability, biodegradability, and biocompatibility of a gene complex. The formation of polyplexes enabled through the electrostatic interactions between the polyethyleneimine-polylactic-acid-polyethylene-glycol and siRNAs can enhance the transformation efficiency by emitting the siRNAs specific to target genes under low pH conditions in the intracellular compartments such as endosomes. The composition using polyethyleneimine-polylactic-acid-polyethylene-glycol for transferring genes can be utilized for drug delivery.
The invention belongs to the field of Chinese herbal preparations, and in particular relates to a pharmaceutic preparation for treating arrhythmia. The pharmaceutic preparation is prepared from the following raw materials in parts by weight: 22 parts of microsorium fortunei ching, 18 parts of nicandra physalodes, 21 parts of all-grass of vigleaf stonecrop, 17 parts of Swertia bimaculata (Sieb. et Zucc.) Hook. f. et Thoms., 25 parts of poria with hostwood, 28 parts of astragalus membranaceus, 25 parts of the root of red-rooted salvia, 15 parts of angelica sinensis, 20 parts of pseudo-ginseng, 25 parts of semen plantaginis, 20 parts of Chinese yam, 25 parts of dandelion, 15 parts of chrysanthemum flowers, 15 parts of schisandra chinensis, 15 parts of rhizoma acori graminei, 15 parts of ligusticum wallichii, and 5 parts of liquorice. The pharmaceutic preparation can treat arrhythmia.
Antifibrinolytic drugs are used extensively for on-demand treatment of severe acute bleeding. Controlling fibrinolysis may also be an effective strategy to prevent or lessen chronic recurring bleeding in bleeding disorders such as hemophilia A (HA), but current antifibrinolytics have unfavorable pharmacokinetic profiles. Here, we developed a long-lasting antifibrinolytic using small interfering RNA (siRNA) targeting plasminogen packaged in clinically used lipid nanoparticles (LNPs) and tested it to determine whether reducing plasmin activity in animal models of HA could decrease bleeding frequency and severity. Treatment with the siRNA-carrying LNPs reduced circulating plasminogen and suppressed fibrinolysis in wild-type and HA mice and dogs. In HA mice, hemostatic efficacy depended on the injury model; plasminogen knockdown improved hemostasis after a saphenous vein injury but not tail vein transection injury, suggesting that saphenous vein injury is a murine bleeding model sensitive to the contribution of fibrinolysis. In dogs with HA, LNPs carrying siRNA targeting plasminogen were as effective at stabilizing clots as tranexamic acid, a clinical antifibrinolytic, and in a pilot study of two dogs with HA, the incidence of spontaneous or excess bleeding was reduced during 4 months of prolonged knockdown. Collectively, these data demonstrate that long-acting antifibrinolytic therapy can be achieved and that it provides hemostatic benefit in animal models of HA.
The proposed study is a prospective, double-blinded, randomized placebo-controlled trial. This study will take place at the Manitoba Men's Health Clinic (Winnipeg, MB, Canada). All patients will undergo blood sampling in a 60 ml syringe containing 8 mL of anticoagulant. Patients will receive 2 treatments 1 month apart. Preparation of PRP and placebo injections will occur in a separate room. Samples of patients in the placebo arm will be discarded and sample of those randomized to the PRP group will be processed via an FDA-approved platelet separator (Magellan Autologous Platelet Separator; Arteriocyte Medical Systems, Hopkinton, MA) to yield approximately 10 mL of PRP. Once prepared, the patient will be placed in the supine position with a tourniquet placed around the base of the penis. A total of 5 mL will be infused in each corpus cavernosum - slowly retracting the needle for better distribution of PRP into the erectile tissue - over a 2-minute period. The whole procedure will be performed under sterile conditions. Following administration, additional compression of the penis will be performed with a dressing placed around the penile shaft. The penile tourniquet will be removed 20 minutes after the injections and patients are released. The placebo group will include a sterile saline injection. Follow-Up Procedures and Evaluations: Follow-up visits will be conducted at months: 1, 3, 6, after the last treatment session and shall include: Measuring IIEF-EF of patients at the clinic at every follow-up visit, as well as reporting and recording adverse events.
INTRODUCTION: Neuropathic pain encompasses multiple diagnoses with detrimental impacts on quality of life and overall health. In older adults, pharmacological management is limited by adverse effects and drug interactions, while surgical management involves perioperative risk. Prior reviews addressing non-pharmacological interventions for neuropathic pain have not focused on this demographic. Therefore, this systematic review synthesizes the evidence regarding the effectiveness of non-pharmacological interventions in reducing neuropathic pain severity in older adults.
METHODS: PubMed, CINAHL, Web of Science, and PsycInfo were searched using key terms, with inclusion criteria of age ≥ 65, neuropathic pain, non-pharmacological intervention, pain severity measurement, English language, peer-reviewed, and either randomized controlled trial (RCT) or quasi-experimental design. In total, 2759 records were identified, with an additional 28 records identified by review of reference lists. After removal of duplicates, 2288 records were screened by title and abstract, 404 full-text articles were assessed, and 19 articles were critically reviewed and synthesized.
RESULTS: Of the 14 RCTs and 5 quasi-experimental studies included in the review, the most common intervention was electric and/or magnetic therapy, followed by acupuncture, mindfulness meditation, exercise, and light therapy. Several studies revealed both statistical and clinical significance, but conclusions were limited by small sample sizes and methodological shortcomings. The interventions were generally safe and acceptable.
CONCLUSIONS: Results should be interpreted with consideration of clinical vs statistical significance, mediators of pain severity, and individual variations in effectiveness. Further research should address multimodal and novel interventions, newer models of care, and technology-based interventions.